Pharmaceutical Industry

Manufacturing AstraZeneca Trade Policy Pharmaceuticals Drug Development Drug Development Corporate Finance Drug Development Stock Market Tariffs

Charles River Labs Reshapes Board and Launches Strategic Review Following Elliott Deal

The agreement brings four new directors, including Elliott’s Steven Barg, and initiates a business evaluation aimed at enhancing shareholder value.

GSK Reports Strong Q1 Results, Confirms Readiness for Potential US Pharma Tariffs

AstraZeneca Reports Q1 Growth and Expands US Investments Amid Regulatory Challenges

Novartis Confirms $23 Billion U.S. Investment with Major Expansion Plans

Novo Nordisk Acquires Chinese Obesity Drug After CagriSema Trial Disappointment

AstraZeneca Announces $2.5 Billion Beijing R&D Hub to Bolster China Presence

Senators Question RFK Jr.'s Mar-a-Lago Dinners with Big Pharma Executives

Alliance Pharma Backs £362m Takeover by DBAY Advisors

Pfizer Considers Relocating Overseas Manufacturing to U.S. Facilities

Eli Lilly Announces $27 Billion Investment in U.S. Manufacturing Expansion

Bristol Myers Squibb Predicts 2025 Revenue Decline, Expands Cost-Cutting Measures

AstraZeneca Reports Strong 2024 Results While Facing China Tax Probe